{"id":282170,"date":"2023-10-24T17:15:22","date_gmt":"2023-10-24T21:15:22","guid":{"rendered":"https:\/\/www.noom.com\/?post_type=b2b_resource&#038;p=282170"},"modified":"2025-03-17T15:55:29","modified_gmt":"2025-03-17T19:55:29","slug":"what-employers-need-to-know-about-trending-weight-loss-medications","status":"publish","type":"b2b_resource","link":"https:\/\/www.noom.com\/au\/health\/resources\/webinars\/what-employers-need-to-know-about-trending-weight-loss-medications\/","title":{"rendered":"What Employers Need To Know About Trending Weight Loss Medications"},"content":{"rendered":"\n<p>In the past year, medications like Ozempic and Wegovy have gained national attention for their weight loss impacts. As the demand for these medications continues to surge, employers face a tough dilemma. The medications can have significant benefits for weight loss, and covering them could lead to direct and indirect savings on obesity-related health issues. Yet, they are costly and often are felt to be needed long term to maintain results. Today, only 22% of U.S. employers cover anti-obesity medication on their health plans.<\/p>\n\n\n\n<p>When many employers are already grappling with the rising costs of healthcare driven by inflation, how should employers decide whether or not to cover weight loss medications?<\/p>\n\n\n\n<p>In this on-demand webinar, Dr. Linda Anegawa, MD, MS, FACP, Chief of Medicine at Noom and award-winning, board-certified physician in Obesity Medicine and Internal Medicine, will share:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Introduction to obesity as a chronic progressive disease needing specialized treatment.<\/li>\n\n\n\n<li>The current landscape of available weight loss medications, and future directions.<\/li>\n\n\n\n<li>Key considerations when evaluating coverage for weight loss medications.<\/li>\n\n\n\n<li>How employers can take a holistic approach to managing pre-obesity and obesity.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>In the past year, medications like Ozempic and Wegovy have gained national attention for their weight loss impacts. As the demand for these medications continues to surge, employers face a tough dilemma. The medications can have significant benefits for weight loss, and covering them could lead to direct and indirect savings on obesity-related health issues. [&hellip;]<\/p>\n","protected":false},"author":85,"featured_media":282239,"menu_order":0,"template":"","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","_searchwp_excluded":"","footnotes":""},"b2b-content-type":[442],"b2b-topic":[],"class_list":["post-282170","b2b_resource","type-b2b_resource","status-publish","has-post-thumbnail","hentry","b2b-content-type-webinars"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.noom.com\/au\/wp-json\/wp\/v2\/b2b_resource\/282170","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.noom.com\/au\/wp-json\/wp\/v2\/b2b_resource"}],"about":[{"href":"https:\/\/www.noom.com\/au\/wp-json\/wp\/v2\/types\/b2b_resource"}],"author":[{"embeddable":true,"href":"https:\/\/www.noom.com\/au\/wp-json\/wp\/v2\/users\/85"}],"version-history":[{"count":0,"href":"https:\/\/www.noom.com\/au\/wp-json\/wp\/v2\/b2b_resource\/282170\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.noom.com\/au\/wp-json\/wp\/v2\/media\/282239"}],"wp:attachment":[{"href":"https:\/\/www.noom.com\/au\/wp-json\/wp\/v2\/media?parent=282170"}],"wp:term":[{"taxonomy":"b2b-content-type","embeddable":true,"href":"https:\/\/www.noom.com\/au\/wp-json\/wp\/v2\/b2b-content-type?post=282170"},{"taxonomy":"b2b-topic","embeddable":true,"href":"https:\/\/www.noom.com\/au\/wp-json\/wp\/v2\/b2b-topic?post=282170"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}